Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 27;13(9):1708. doi: 10.3390/v13091708

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Levels of anti-NP IgG in sera of mice after vaccination with MVA vaccines that encoded NP combined with other antigens. Levels of serum anti-NP IgG were analyzed by ELISA. “Prime” refers to intranasal instillation of sublethal PR8 on day 0; first immunization using an MVA vaccine occurred on day 22; second immunization using MVA vaccines occurred on day 43. MVAtor alone did not result in serum anti-NP IgG antibody levels but priming using PR8 generated high IgG anti-NP levels. Squares depict single insert encoding M1 + METRC + NP; triangles depict a blend of individual M1, METRC and NP constructs; circles depict MVAtor controls. Filled symbols depict MVA vaccine treatments; empty symbols depict non-lethal (10% weight loss) PR8 infection as a priming event. * Anti-NP IgG ELISA were not performed using sera of this group.